Supplemental Table 1: Changes in Serum Creatinine Following Treatment with Bardoxolone Methyl[a]

	N	Response Rate[b]	Baseline Serum Creatinine (mg/dL)	Decrease in Serum Creatinine[c]	Mean Baseline eGFR[d] (ml/min/1.73 m^2)	Increase in eGFR[c]
All Patients	36	86%	1.0	16.9% ± 1.8%	74.4 ± 3.5	26.4% ± 3.2%
Patients in 900 mg cohort	20	100%	1.0	21.2% ± 2.0%	73.4 ± 5.1	33.9% ± 4.2%
eGFR[e] <90 ml/min/1.73 m^2	26	92%	1.1	18.3% ± 2.2%	64.8 ± 3.1	29.0% ± 3.9%
eGFR[e] <60 ml/min/1.73 m^2	10	100%	1.4	21.9% ± 3.2%	48.7 ± 2.7	35.6% ± 6.8%
eGFR[e] ≥60 ml/min/1.73 m^2	26	81%	0.9	15.0% ± 2.1%	84.4 ± 2.9	22.9% ± 3.5%

[a] Excludes patients without baseline and Day 21 Cycle 1 serum creatinine measurements
[b] Percentage of patients with lower serum creatinine values on Day 21 of Cycle 1 compared to baseline
[c] Percent change from baseline to Day 21 of Cycle 1
[d] eGFR was calculated using the Modification of Diet in Renal Disease Study (MDRD) formula
[e] eGFR at baseline